Autolus Therapeutics plc American Depositary Share - AUTL STOCK NEWS

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in several investor conferences throughout April 2021. Key events include the Wells Fargo Annual Biotech Corporate Access on April 6 and 8, and the 20th Annual Needham Virtual Healthcare Conference on April 14, where the CEO and CFO will engage in a Fireside Chat. Additionally, Autolus will partake in the Raymond James Oncology Summit on April 22 and Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day on April 28. This participation highlights Autolus's commitment to advancing its next-generation T cell therapies for cancer treatment.

Autolus Therapeutics (Nasdaq: AUTL) has received PRIME designation from the European Medicines Agency for its CAR T cell therapy AUTO1, aimed at treating relapsed/refractory adult B-acute lymphocytic leukemia. This designation enhances support for development and review, potentially expediting access to patients with unmet medical needs. AUTO1 showcases promising activity and safety data, with ongoing studies evaluating its effectiveness. The FELIX study will enroll 100 patients to assess overall response rate and safety, positioning AUTO1 as a potential game-changer in treating this condition.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced a strategic shift in its manufacturing operations for AUTO1, moving to a more cost-effective commercial supply strategy based in the UK. This change will utilize existing facilities and a new site to enhance its operational capacity. Additionally, the company has mutually terminated its lease in Rockville, MD, resulting in a cash payment and the cessation of lease obligations, which aims to further reduce costs.

Autolus Therapeutics plc (Nasdaq: AUTL) announced its operational and financial results for Q4 and FY 2020, showcasing a robust financial position after raising $131 million, enabling a cash runway into H1 2023. The company's AUTO1 program for adult B-ALL has shown promising results, with an 84% MRD-negative response in treated patients. However, net loss rose to $142.1 million in 2020, compared to $123.8 million in 2019. Management expects multiple clinical readouts in 2021 and 2022, including updates on AUTO1 and other CAR T therapies.

Autolus Therapeutics plc (Nasdaq: AUTL) announced that CEO Dr. Christian Itin will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will feature one-on-one meetings with participants. A live audio webcast of the presentation will be available on Autolus’ investor relations page starting March 9 at 7:00 a.m. EST, with an archived replay accessible for 90 days. Autolus is focused on developing next-generation programmed T cell therapies aimed at treating various cancers.

Autolus Therapeutics plc (Nasdaq: AUTL) has successfully closed a public offering of 16,428,572 ADSs at a price of $7.00 each, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option by underwriters for an additional 2,142,857 ADSs. J.P. Morgan and Wells Fargo Securities were the joint bookrunners for this transaction. The funds will support the development of Autolus' next-generation T cell therapies aimed at treating cancer, leveraging advanced programming technologies to improve efficacy against malignancies.

Autolus Therapeutics plc (Nasdaq: AUTL) has priced a public offering of 14,285,715 American Depositary Shares (ADSs) at $7.00 each, aiming to raise approximately $100 million. The offering is expected to close on February 12, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,142,857 ADSs.

This offering follows an effective shelf registration statement with the SEC, and all securities will be offered solely through a prospectus. Autolus is focused on developing advanced T cell therapies for cancer treatment.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced a public offering of up to $100 million of its American Depositary Shares (ADSs). The offering, managed by J.P. Morgan and Wells Fargo Securities, may include an additional $15 million option for underwriters. This move is part of the company's strategy to support its development of next-generation T cell therapies for cancer. The offering is subject to market conditions, with no assurance regarding completion or terms.

Autolus Therapeutics (Nasdaq: AUTL) will disclose its Q4 2020 and full-year financial results on March 4, 2021, prior to U.S. market open. The company develops next-generation programmed T cell therapies and is expected to provide operational highlights during this release. A conference call will occur at 8:30 am ET, featuring a general business update and an opportunity for investors to engage. For those interested, access to the call will be available via the company’s website and dedicated phone lines.